HIV-specific T cells can be generated against conserved non-escaped HIV epitopes for use in a phase I clinical trial: Pre-clinical validations and implications for a cure strategy for HIV

      While the adoptive transfer of antigen-specific T cells has shown success for patients with cancer or post-transplant viral infections, extension to the HIV setting has been relatively limited. Infusions of HIV-specific CD8+ T cells targeting single epitopes have resulted in immune escape and limited persistence of T cells in vivo. To address these limitations, developing effective HIV T cell therapies has two goals: (1) exposure and recognition of latently infected cells and (2) elimination of latently infected cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect